Teva Migraine Drug Patent Suit Against Eli Lilly Can Proceed

March 16, 2022, 4:03 PM UTC

Teva Pharmaceuticals International GmbH can proceed with a suit alleging that Eli Lilly & Co. induced infringement of two patents that claim methods for treating persistent migraine headaches, a federal court in Massachusetts said.

The drug maker’s complaint plausibly alleged that Eli Lilly knew of the patents, knowingly induced infringing acts by others, and acted with a specific intent to induce infringement, the U.S. District Court for the District of Massachusetts said. It adequately put Eli Lilly on notice of the claims, the court said.

The case involves two method patents for using Teva’s Ajovy to treat refractory migraines—a type ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.